Stock Events

Stock Events

Immunome 

$22.2
40
+$0+0% Wednesday 07:29

Statistics

Day High
22.25
Day Low
20.3
52W High
-
52W Low
-
Volume
6,906
Avg. Volume
-
Mkt Cap
2.51B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

7MayExpected
Q3 2025
Q4 2025
Next
-0.76
-0.69
-0.62
-0.55
Expected EPS
-0.55
Actual EPS
N/A

Financials

-3,059.99%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
13.88MRevenue
-424.79MNet Income

Analyst Ratings

$35.00Average Price Target
The highest estimate is 40.00.
From 8 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow IMNM.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Moderna
MRNA
Mkt Cap10.61B
Moderna is a leader in mRNA technology, which can be used for developing vaccines and therapeutics, competing with Immunome's antibody discovery platform.
BioNTech
BNTX
Mkt Cap24.99B
BioNTech, similar to Moderna, focuses on mRNA technology for vaccines, directly competing in the infectious disease space with Immunome.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals develops monoclonal antibodies for the treatment of various diseases, directly competing with Immunome's antibody-based therapies.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences focuses on antiviral drugs for infections like HIV, hepatitis B, hepatitis C, and influenza, competing with Immunome's infectious disease focus.
AMGEN
AMGN
Mkt Cap160.66B
Amgen, a biotech giant, has a broad portfolio including immunotherapies and oncology, overlapping with Immunome's therapeutic areas.
Adaptive Biotechnologies
ADPT
Mkt Cap2.64B
Adaptive Biotechnologies works on the immune-driven medicine space, particularly in using the body's immune response to disease, competing with Immunome's approach to harnessing the immune system.
Novavax
NVAX
Mkt Cap1.36B
Novavax is focused on developing vaccines for infectious diseases, including COVID-19, competing in the same space as Immunome's infectious disease research.
Pfizer
PFE
Mkt Cap140.15B
Pfizer, with its broad range of vaccines and therapeutics, competes across several areas, including infectious diseases, where Immunome is also active.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson, through its Janssen Pharmaceuticals division, develops treatments and vaccines for infectious diseases, competing with Immunome.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals focuses on serious chronic diseases, including cystic fibrosis, where Immunome's novel antibody approaches could potentially compete.

About

Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
Show more...
CEO
ISIN
US45257U1088

Listings

XNAS
US
IMNM
BOATS
BOATS
IMNM.BOATS

0 Comments

Share your thoughts

FAQ

What is Immunome stock price today?▼
The current price of IMNM.BOATS is $22.2 USD — it has increased by +0% in the past 24 hours. Watch Immunome stock price performance more closely on the chart.
What is Immunome stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Immunome stocks are traded under the ticker IMNM.BOATS.
What is Immunome market cap?▼
Today Immunome has the market capitalization of 2.51B
When is the next Immunome earnings date?▼
Immunome is going to release the next earnings report on May 07, 2026.
What were Immunome earnings last quarter?▼
IMNM.BOATS earnings for the last quarter are -0.76 USD per share, whereas the estimation was -0.59 USD resulting in a -28.78% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Immunome revenue for the last year?▼
Immunome revenue for the last year amounts to 13.88M USD.
What is Immunome net income for the last year?▼
IMNM.BOATS net income for the last year is -424.79M USD.
When did Immunome complete a stock split?▼
Immunome has not had any recent stock splits.